erlotinib has been researched along with methotrexate in 8 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (methotrexate) | Trials (methotrexate) | Recent Studies (post-2010) (methotrexate) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 41,593 | 5,666 | 11,969 |
| Protein | Taxonomy | erlotinib (IC50) | methotrexate (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.8 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 0.211 | |
| Toll-like receptor 4 | Homo sapiens (human) | 1.04 | |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | 0.08 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0522 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.0331 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0348 | |
| Dihydrofolate reductase | Gallus gallus (chicken) | 0.0545 | |
| Dihydrofolate reductase | Enterococcus faecium | 0.0014 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0138 | |
| Thymidylate synthase | Homo sapiens (human) | 0.343 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0147 | |
| Thymidylate synthase | Escherichia coli K-12 | 0.0181 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1529 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.084 | |
| Folate receptor beta | Homo sapiens (human) | 0.1585 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0011 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.0012 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2263 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0717 | |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | 0.0014 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.01 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.01 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Reduced folate transporter | Homo sapiens (human) | 0.012 | |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | 0.0174 | |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | 3.2 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0547 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.11 | |
| Dihydrofolate reductase | Bacillus anthracis | 0.0136 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0047 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.1207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Namjoshi, OA; Thorpe, JE; Yu, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for erlotinib and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for erlotinib and methotrexate
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastati
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Design; Humans; Melanoma, Experimental; Mice; Mice, Nude; Microwaves; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |